Oncology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib
Annals of Oncology, 11/10/09

Thiam R et al. – The SLD threshold of –10% gave the most significant difference. It divided patients into 256 responders and 78 nonresponders (median PFS 11.1 and 5.6 months). The same –10% threshold was found using the ROC analysis. Results were confirmed on the external validation cohort.

Methods

334 mRCC patients treated with sunitinib
Tested thresholds from –45% to +10%
Patients classified as ‘responders’ when best relative variation of sum of longest diameters (&Delta SLD) reached tested threshold and as ‘nonresponders’ otherwise
For each tested threshold, median PFS of 2 groups compared
Receiver operating characteristic (ROC) analysis carried out among 103 patients that progressed during follow-up
‘Optimal’ threshold retested on independent cohort of 39 patients

Results

The &DeltaSLD threshold of –10% gave the most significant difference
It divided patients into 256 responders and 78 nonresponders (median PFS 11.1 and 5.6 months)
Same –10% threshold found using ROC analysis
Results confirmed on external validation cohort

<< Previous
Analysis of the expression of hyaluronan in intraductal and...

Next >>
Pregnancy after breast cancer: The importance of active...